MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor

Jing-Yan Yang, Yang Li, Qian Wang, Wen-Jia Zhou, Yan-Ni Yan, Wen-Bin Wei

Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Lab, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Capital Medical University, Beijing 100730, China.

Abstract

Background: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. It has been demonstrated that microRNA-145 (miR-145) is correlated with the progression of various cancers by regulating the expression of multiple target genes, especially a number of genes that regulate angiogenesis and proliferation. However, the underlying mechanisms of miR-145 in tumor angiogenesis of UM are still not well illustrated. Thus, we aimed to explore the potential target genes or pathways regulated by miR-145 in UM and the effect of miR-145 on invasion and angiogenesis.

Methods: Totally, 24 choroid samples were collected in our study, including 12 UM samples and 12 normal uveal tissues. The expression of neuroblastoma RAS viral oncogene homolog (N-RAS), phosphorylated protein kinase B (p-AKT), and vascular endothelial growth factor (VEGF) in UM tissues and normal uveal tissues was analyzed using Western blotting analysis. Lentivirus expression system was used to construct MUM-2B and OCM-1 cell lines with stable overexpression of miR-145. Transwell and endothelial cell tube formation assay were used to measure the effects of miR-145 on the invasion and angiogenesis of UM in vitro. The downstream target genes of miR-145 were predicted by bioinformatics and confirmed using a luciferase assay. BALB/c nude mice models were established to investigate the mechanisms of miR-145 on tumor growth and angiogenesis in vivo. Group data comparisons were performed using analysis of Student’s t test. A two-tailed P < 0.05 was considered as statistically significant.

Results: The results of Western blotting analysis indicated that the expressions of N-RAS (1.10 ± 0.35 vs. 0.41 ± 0.36, t = 3.997, P = 0.012), p-AKT (1.16 ± 0.22 vs. 0.57 ± 0.03, t = 7.05, P = 0.001), and VEGF (0.97 ± 0.32 vs. 0.45 ± 0.21, t = 3.314, P = 0.008) in UM tumor tissues were significantly higher than those in normal uveal tissue. Luciferase assay demonstrated N-RAS and VEGF as downstream targets of miR-145. Moreover, tube formation assay revealed that miR-145-transfected human microvascular endothelial cell line formed shorter tube length (36.10 ± 1.19 vs. 406.67 ± 95.6, t = 21.27, P = 0.003) and less branch points (350.00 ± 19.97 vs. 406.67 ± 17.62, t = 3.685, P = 0.021) as compared with controls. In addition, the numbers of invaded MUM-2B and OCM-1 cells with miR-145 overexpression were significantly lower than the controls (35.7 ± 3.3 vs. 279.1 ± 4.9, t = 273.75, P < 0.001 and 69.5 ± 4.4 vs. 95.6 ± 4.7, t = 21.27, P < 0.001, respectively). In vivo, xenografts expressing miR-145 had smaller sizes (miR-145 vs. miR-scr, 717.41 ± 502.62 mm³ vs. 1694.80 ± 904.33 mm³, t = 2.314, P = 0.045) and lower weights (miR-145 vs. miR-scr, 0.74 ± 0.46 g vs. 1.65 ± 0.85 g, t = 2.295, P = 0.045).

Conclusion: Our results indicated that miR-145 is an important tumor suppressor and the inhibitory strategies against N-RAS/VEGF signaling pathway might be potential therapeutic applications for UM in the future.

Keywords: Uveal melanoma; Vascular endothelial growth factor A; Neuroblastoma RAS viral oncogene homolog; microRNA-145; Angiogenesis

Introduction

Uveal melanoma (UM), which arises from melanocytes, is the most common primary intraocular malignancy in adults and is associated with the development of systemic metastases in over half of the patients. Previous studies have revealed that increased angiogenesis is associated with higher metastasis and mortality rate in UM. However, the precise molecular underpinnings are still unknown. Therefore, strategies based on antiangiogenic and antimetastatic mechanisms may provide potential treatment for UM. MicroRNAs (miRNAs) are a group of endogenous non-coding RNAs that regulate gene expres-

Access this article online

Quick Response Code: 

Website: www.cmj.org

DOI: 10.1097/CM9.0000000000008075

Correspondence to: Prof. Wen-Bin Wei, Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Ophthalmology and Visual Science Key Lab, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Capital Medical University, Beijing 100730, China

E-Mail: weiwbnbr1@163.com

Received: 26-02-2020

© 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2020;133(16)
sion by repressing the stability of conventional miRNAs and/or inhibiting their translation into proteins. Recent studies have demonstrated that miRNAs are differentially expressed in lung, nasopharyngeal, gastric and breast cancers, and may function as either oncogenes or tumor suppressors by controlling the expression of their target genes. The overexpression of several miRNAs, such as miR-145 and miR-224, has been demonstrated an inhibitory role in migration, proliferation, and invasion of UM cells.

MicroRNA-145 (miR-145), a widely studied miRNA, is downregulated in various tumors. In our previous study, we reported that miR-145 was downregulated in UM tissues and cell lines. In addition, both bioinformatics prediction and experimental results indicated that miR-145 might inhibit tumor angiogenesis and growth in UM. Angiogenesis is of great importance in tumorigenesis and tumor development. Vascular endothelial growth factor (VEGF), regulated by Ras, is crucial in angiogenesis among all the angiogenic factors. Thus, we may speculate that miR-145 regulates the downstream genes of Ras signaling, including neuroblastoma RAS viral oncogene homolog (N-RAS) and VEGF. Nevertheless, whether these genes or pathways are regulated by miR-145 in UM and the effect of miR-145 on invasion and angiogenesis still needs further study.

In this study, we aimed to explore the potential target genes or pathways regulated by miR-145 in UM and the effect of miR-145 on invasion and angiogenesis in vitro and in vivo.

Methods

Ethical approval

Animal studies were approved by the animal care committee (No. GSZE0199323) and clinical studies were approved by the ethics committee of Beijing Tongren Hospital of Capital Medical University (No.TRECKY2015-017). All UM patients provided written informed consent to this study.

Human tissue samples

Fresh UM tumor samples were obtained from Beijing Tongren Hospital, China, from November 2016 to December 2017. None of the UM patients were given radiation or chemotherapy therapy prior to the surgery. UM samples were collected at surgery, immediately frozen in liquid nitrogen and stored overnight after removal, and then were transferred to −80°C for storage until use. The normal uveal tissues were obtained from Tongren Eye Bank (Beijing, China).

Cell culture

Human UM cell lines (OCM-1 and MUM-2B) were purchased from Procell (PROCELL Life Science & Technology Co., Ltd., Wuhan, China). MUM-2B and OCM-1 cells were maintained in RPMI 1640 (Gibco, California, USA) and Dulbecco’s modified Eagle’s medium (Gibco, California, USA), respectively, supplemented with 10% fetal bovine serum (HyClone, Logan, Utah, USA) in a humidified atmosphere at 37°C under 5% CO₂. For experimental purposes, the cells were cultured in 35 or 60-mm plastic Petri dishes. Cells were seeded at a density of 3000–5000 cells/cm², and experiments were initiated when the cells had reached subconfluence.

Western blotting analysis

Cell lysates were collected using RIPA lysis buffer (Shanghai Genechem Co., Ltd., China) supplemented with protease inhibitor and phosphatase inhibitor. The concentration of total protein was determined by the Pierce Coomassie (Bradford) Protein Assay Kit (Thermo Fisher Scientific, USA). Then, a total of 20 µg protein samples were electrophoresed on polyacrylamide gels and transferred to polyvinylidene fluoride membranes. The membranes were blocked with 5% fat-free milk powder in TBS-T (pH 7.6; 20 mmol/L Tris-HCl, 100 mmol/L NaCl, and 0.01% Tween 20) at room temperature for 2 hours and incubated with the primary antibodies targeting human mammalian target of rapamycin (mTOR), p-AKT, AKT (Cell Signaling Technology, USA), N-RAS, and VEGFA (Thermo Fisher Scientific, USA) overnight at 4°C. After washing three times, the membrane was hybridized with horseradish peroxidase-conjugated secondary antibody (dilution factor, 1:10,000) at room temperature for 2 hours. The concentrations of all antibodies used in this study were based on the manufacturer’s instructions. The signal was developed using the Enhanced Chemiluminescence Plus kit. The images of Western blots were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA) for densitometry calculation.

Target gene prediction

The miRNA target prediction was performed by miRanda (Memorial Sloan-Kettering Cancer Center, New York, USA) and TargetScan (Department of Biology, MA Institute of Technology, Cambridge, MA, USA) based on target sequence, structure, and function.

Lentivirus expression system

Viral supernatant was obtained by the transfection of HEK293T cells with pLemiR-145 or pLemiR-scrambled control (pLemiR-scr). For stable transfection of miR-145, MUM-2B and OCM-1 cells were initially plated at a density of 2 × 10⁵ cells in a six-well plate for 24 hours and then infected with lentiviral particles using polybrene (8 mg/mL) (Sigma-Aldrich, Germany). After 24 hours of incubation at 37°C, the medium was removed and fresh medium was added. Stably transfected cells (miR-145 overexpressing or control) were selected using amphotericin (100 µg/mL, Invitrogen, Madison, Wisconsin, USA) for 4 days. The miR-145 positive colonies were identified by qRT-PCR.

Luciferase activity assay

The wild-type (WT) 3′ untranslated region (3′-UTR) of NRAS or VEGF containing the miR-145–5p binding sites was amplified and cloned downstream of the firefly luciferase gene in the pGL3 control vector (Promega,
Transwell and endothelial cell tube formation assays

OCM-1 (1 × 10^5) and MUM-2B (1 × 10^5) cells were seeded in each well with an 8-μm pore membrane in the upper chambers of transwell culture plates (Corning, Shanghai, China). After 16 hours of incubation, the non-invading cells on the upper chamber were scraped using a cotton swab, and the membranes were then fixed with 100% methanol and stained with 0.5% crystal violet. The cells attached to the lower surface were counted and imaged under an inverted microscope (Shanghai Caikon Optical Instrument Co., Ltd., China) at × 200 magnification in nine randomly chosen fields.

For the endothelial cell tube formation assay, 55-mL growth factor-reduced Matrigel was polymerized on 96-well plates. Human microvascular endothelial cells (HMEC-1) were serum-starved in medium for 2 hours. The cells were suspended in the medium extracted from each group, then added to the Matrigel-coated wells at a density of 3 × 10^4 cells/well and incubated at 37°C for 24 hours. Tube formation of the endothelial cell was defined as the appearance of intraluminal space inside the tube and the quantification of anti-angiogenic activity was calculated by measuring the tube length and the number of branch points under a light microscope with an image analyzer (Confocal Quantitative Image Cytometer CQ1 software, Japan).

Animal care and tumor implantation

For the in vivo tumor growth assay, 12 four-week-old female BALB/c nude mice (six per group), maintained in pathogen-free conditions with standard diets, were injected subcutaneously in the right side of the axilla with 3 × 10^6 OCM-1 cells transfected with miR-145–5p mimic vector or its negative control vector. Fifteen days after the injections, the tumor volumes and body weights of the animals were measured every 3 days. Mice were sacrificed and the xenografts were removed at the indicated time. All mice were sacrificed according to a standard procedure after 30 days, and the tumors were harvested and weighed. The volume of each tumor was calculated according to the formula V = π/6 × L × W × W (L and W are the length and the width of the tumor, respectively), measured with a sliding caliper. Analysis of the targets and signaling molecules, including N-RAS, AKT, p-AKT, mTOR, and VEGF, in the xenografts were examined by Western blotting.

Statistical analysis

All statistical analyses were performed using SPSS statistical software (version 25.0 for Windows, SPSS IBM, New York, USA). All experimental data are represented as mean ± standard deviation. Group data comparisons were performed using Student’s t-test analysis. A two-tailed P < 0.05 was considered as statistically significant.

Results

Expression of N-RAS and VEGF in primary UM and normal controls

In total, 24 choroid samples were collected in our study, of which 12 were UM samples and 12 were normal uveal tissues. The UM patients and normal controls did not differ significantly in age or gender. No one has ciliary body involved in UM group. The mean tumor basal diameter was 15.14 ± 3.85 mm and mean tumor thickness was 12.55 ± 4.35 mm at diagnosis. Clinical and pathological information of UM samples used in current work is listed in Table 1. We examined the expression of N-RAS-VEGF pathway components, including N-RAS, AKT, p-AKT, mTOR, and VEGF, in UM tissues compared with normal controls. The results indicated that the expression of

| Sample number | Age at diagnosis (years) | Time to Enucleation (months) | Gender | Eye | Location | Tumor basal diameter (mm) | Tumor Thickness (mm) | Tumor cytology | Scleral invasion |
|---------------|-------------------------|-----------------------------|--------|-----|----------|--------------------------|----------------------|----------------|----------------|
| P1            | 53                      | 2                           | Male   | OD  | Choroid  | 16.1                    | 17.1                 | Spindle        | No             |
| P2            | 52                      | 4                           | Male   | OS  | Choroid  | 18.8                    | 17.6                 | Epithelioid     | No             |
| P3            | 28                      | 12                          | Male   | OS  | Choroid  | 15.4                    | 6.3                  | Mixed          | No             |
| P4            | 48                      | 5                           | Male   | OD  | Choroid  | 11.7                    | 10.1                 | Epithelioid     | No             |
| P5            | 34                      | 3                           | Male   | OD  | Choroid  | 10.1                    | 12.9                 | Mixed          | No             |
| P6            | 25                      | 4                           | Male   | OS  | Choroid  | 21.2                    | 16.2                 | Mixed          | No             |
| P7            | 47                      | 9                           | Female | OD  | Choroid  | 11.7                    | 6.5                  | Mixed          | No             |
| P8            | 35                      | 3                           | Male   | OD  | Choroid  | 15.5                    | 13.2                 | Mixed          | No             |
| P9            | 52                      | 3                           | Female | OS  | Choroid  | 18.2                    | 14.6                 | Spindle        | No             |
| P10           | 48                      | 12                          | Female | OS  | Choroid  | 10.6                    | 6.1                  | Mixed          | No             |
| P11           | 59                      | 3                           | Female | OD  | Choroid  | 12.3                    | 12.9                 | Spindle        | No             |
| P12           | 51                      | 7                           | Male   | OS  | Choroid  | 20.1                    | 17.1                 | Mixed          | No             |

OD: Oculus dexter; OS: Oculus sinister; UM: Uveal melanoma.
In our previous study,[10] we demonstrated that miR-145-5p directly targets N-RAS and VEGF and VEGF (0.97 ± 0.21 vs. 0.45 ± 0.21, t = 3.314, P = 0.008) in UM tumor tissues was significantly higher than that in normal uveal tissue, as examined by Western blotting [Figure 1A and 1B].

Mir-145-5p directly targets N-RAS and VEGF

In our previous study,[10] we demonstrated that miR-145-5p was significantly downregulated in UM tissues compared with normal uveal tissues. Thus, it could be speculated that miR-145-5p might directly modulate N-RAS and VEGF expression in UM. To further understand the molecular mechanism of miR-145 in inhibiting angiogenesis and cell invasion, we searched for potential targets of miR-145 using miRanda (Memorial Sloan-Kettering Cancer Center, New York) and TargetScan (Department of Biology, MA Institute of Technology, Cambridge, MA). We found that NRAS and VEGFA could be the potential targets of miR-145 [Figure 2A]. To validate these miR-145 targets, luciferase activity assays were performed in HEK 293T cells. The luciferase activities of vectors carrying wild type VEGFA 3’-UTR (WT) and NRAS 3’-UTR (WT) were attenuated by cotransfection with miR-145-5p, while there was no significant difference in groups transfected with mutant 3’-UTR of VEGFA or NRAS and the negative control of miR-145-5p [Figure 2B]. These data demonstrated that VEGFA and NRAS might be the direct targets of miR-145-5p.

Mir-145 inhibits angiogenesis and invasion in vitro

Since our data demonstrated that VEGFA and N-RAS were directly targeted genes regulated by miR-145-5p, we next investigated the effects of miR-145 on tumor angiogenesis and invasion in vitro. A tube formation assay using endothelial cells was performed and the quantification of angiogenic activity was calculated by measuring the tube length and number of branch points under a light microscope. The results showed that miR-145-transfected HMEC-1 cells formed shorter tube length (36.10 ± 1.51 mm vs. 42.91 ± 0.94 mm, t = 6.603, P = 0.003) and decreased branch points (350.00 ± 19.97 vs. 406.67 ± 17.62, t = 3.685, P = 0.021) as compared with controls, indicating a decreased angiogenic activity [Figure 3A]. Transwell assays were performed to investigate the effects of upregulation of miR-145-5p on the invasion of UM cells in vitro. MUM-2B and OCM-1 cells were transfected with miR-145-5p, which was confirmed by qPCR assay [Figure 3B]. The numbers of invaded MUM-2B and OCM-1 cells with miR-145 overexpression were significantly lower than the controls (35.7 ± 3.3 vs. 279.1 ± 4.9, t = 273.75, P < 0.001 and 69.5 ± 4.4 vs. 95.6 ± 4.7, t = 21.27, P < 0.001, respectively). These results suggested that cell invasion ability was significantly decreased by overexpression of miR-145 in MUM-2B and OCM-1 cells [Figure 3C and Figure 3D].

Mir-145 inhibits tumor growth and angiogenesis in vivo

To investigate the effect of miR-145 on tumor growth and angiogenesis in vivo, we injected lentivirus-miR-scr- and lentivirus-miR-145-transduced OCM-1 cells into nude mice. We found that miR-145 expression in UM cells significantly reduced xenograft tumor growth and angiogenesis compared with those transfected with empty vector (mock). At 30 days after subcutaneous injection, xenografts expressing miR-145 had smaller sizes (miR-145 vs. miR-scr, 717.41 ± 502.62 mm³ vs. 1694.80 ± 904.33 mm³, t = 2.314, P = 0.045) and lower weights (miR-145 vs. miR-scr, 0.46 g vs. 1.65 ± 0.85 g, t = 2.295, P = 0.045) [Figure 4A and 4B]. In addition, the expression of N-RAS (0.20 ± 0.09 vs. 0.70 ± 0.09, t = 9.715, P < 0.001), p-AKT (0.18 ± 0.09 vs. 0.72 ± 0.11, t = 9.304, P < 0.001), m-TOR (0.07 ± 0.02 vs. 0.40 ± 0.02, t = 27.116, P < 0.001) and VEGF (0.36 ± 0.07 vs. 0.76 ± 0.29, t = 3.327, P = 0.018) were also reduced in stable miR-145 precursor transfected xenografts compared with controls, as examined by Western blotting. [Figure 4C].
Discussion

It is well known that VEGF is produced by cells stimulating vasculogenesis and angiogenesis. Overexpression of VEGF could lead to disease when blood circulation is inadequate. Tumors cannot grow beyond a limited size without an adequate blood supply, while VEGF can promote endothelial cell proliferation and play a significant role in tumor angiogenesis and growth.\[13,14\] The VEGF gene has been demonstrated to be correlated with the invasion and metastasis of various cancers including UM.\[15-17\] In the current study, we investigated whether the VEGF and NRAS-VEGF pathway components, including NRAS, p-AKT, and mTOR, are involved in UM tissues. The results indicated that the expression of NRAS, p-AKT, and VEGF in UM tumor tissues was significantly higher than that in normal uveal tissue, as examined by Western blotting. The results of our study were in agreement with former studies showing that VEGF-A is overexpressed in several UM cell lines, including MEL-270, OM-431, OMM-2.3, and OMM-2.5.\[15,18,19\]

It has been documented that the expression of miR-145 in vascular smooth muscle cells has specific connection with the proliferation of abnormal vascular intima.\[20\] MiR-145 is correlated with the progression of various cancers by regulating the expression of multiple target genes, especially a number of genes that regulate angiogenesis and proliferation.\[21-23\] Our previous work showed that the expression of miR-145 was significantly lower in UM tissues than normal uveal samples. Overexpression of miR-145 suppressed cell proliferation by blocking cells in G1 phase from entering S phase and promoted cell apoptosis in UM cells.\[10\] However, the underlying mechanisms by which miR-145–5p regulates UM angiogenesis remain unknown. To investigate the function of miR-145 in the invasion and metastasis of the cells, we performed transwell invasion assays and endothelial cell tube formation assays. The results revealed that the overexpression of miR-145 could inhibit the invasion and angiopoiesis of UM cells. The inhibitory effects of miR-145–5p on tumor cell lines have also been confirmed in several studies. Fan et al.\[14\] reported that VEGF expression in the miR-145 transfected group was significantly downregulated...
compared with that in the blank group in osteosarcoma cells. Boufraqech et al. [24] suggested that miR-145 could regulate thyroid cancer growth by mediating the PI3K/Akt pathway and may serve as a useful diagnostic marker for thyroid cancer diagnosis. Therefore, miR-145 may be used as a potential diagnostic biomarker that plays an important role as a tumor suppressor in UM.

To further investigate the effect of miR-145 on tumor growth and angiogenesis in vivo, we injected lentivirus-miR-scr- and lentivirus-miR-145-transduced OCM-1 cells into nude mice. We found that xenografts expressing miR-145 had smaller sizes and lower weights. In addition, the expression of p-AKT, m-TOR, and VEGF was also reduced by stable transfection of the miR-145 precursor. Furthermore, we constructed luciferase-UTR vectors carrying VEGF 3′ UTR and N-RAS 3′ UTR as well as their corresponding mutants. The bioinformatic analysis results indicated that VEGF and N-RAS might be the direct targets of miR-145-5p in UM angiogenesis. These results were consistent with the previous findings. Shi et al. [25] have revealed IGF-I/IRS1 as direct targets of miR-145 in colon cancer, indicating the complex regulatory network of this miRNA in tumors. It is also been demonstrated that miR-145 could suppress tumor angiogenesis and growth by targeting NRAS signaling in breast cancer and colorectal cancer. [26, 27]

The observed different effects of miR-145-5p in diverse tumors are very promising for application as diagnostic or prognostic biomarkers. To better understand the miR-145-mediated network on tumor angiogenesis, emphasis should be on searching for more target genes and exploring potential target therapies. When the results of our study are discussed, its limitations should be considered. First, although the ration of the tumor growth is higher in subcutaneous xenograft models and the lesions are easy to be removed, inoculated xenograft models (such as anterior chamber injection) could provide specific features of the ocular immune system leading to an intraocular tumor microenvironment. Further research on intraocular xenograft models is strongly needed, so that we can better understand the unique characteristics of UM. Second, since liver metastases occur in 95% of patients with metastatic UM, liver metastasis mouse models may offer a more detailed investigation of the biological behavior of metastatic UM cells. Such issues are expected to be addressed in our future work.

In conclusion, our results suggest that miR-145 suppresses tumor growth and invasion by directly targeting the NRAS and VEGF signaling pathways in UM. The findings of our study also have identified miR-145 as an antiangiogenic factor both in vitro and in vivo, which could have important implications for further understanding the
signaling mechanisms involved in regulating UM angiogenesis. Accordingly, there is a good reason to speculate that miR-145 is an important tumor suppressor and the inhibitory strategies against the N-RAS/VEGF signaling pathway might be potential therapeutic applications for UM in the future.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (No. 81570891), Beijing Natural Science Foundation (No. 7151003), Beijing Municipal Administration of Hospitals’ Ascent Plan (No. DFLL20150201), Advanced Health Care Professionals Development Project of Beijing Municipal Health Bureau (No. 2014-2-003), The Capital Health Research and Development of Special (No. 2016-1-2051), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (No. ZYLX201307), and Science & Technology Project of Beijing Municipal Science & Technology Commission (Nos. Z181100001818003 and Z151100001615052).
Confl icts of interest
None.

References
1. Fry MV, Augsburger JJ, Corrêa ZM. Clinical Features, metastasis, and survival in patients younger than 21 years with posterior uveal melanoma. JAMA Ophthalmol 2019;137:75–81. doi: 10.1001/ jamaophthalmol.2018.5112.

2. Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, et al. Tumour angiogenesis in uveal melanoma is related to genetic evolution. Cancers (Basel) 2019;11. pii: E979. doi: 10.3390/cancers11070979.

3. Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, et al. An insight of microRNAs performance in carcinogenesis and tumorigenesis: an overview of cancer therapy. Life Sci 2020;240:117077. doi: 10.1016/j.lfs.2019.117077.

4. Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal 2015;8. re.3. doi: 10.1126/scisignal.2005825.

5. Sandovál-Bórquez A, Polakovichova I, Carrasco-Véliz N, Lobos-González L, Riquelme I, Carrasco-Avino G, et al. MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer. Clin Epigenetics 2017;9:114. doi: 10.1186/s13148-017-0413-8.

6. Cantini L, Bertoli G, Cava C, Dubois T, Zinovoy A, Caselle M, et al. Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer. Nucleic Acids Res 2019;47:2205–2215. doi: 10.1093/nar/gkz016.

7. Wu S, Chen H, Han N, Zhang C, Yan H. Long noncoding RNA PVT1 silencing prevents the development of uveal melanoma by impairing MicroRNA-17-3p-dependent MDM2 upregulation. Invest Ophthalmol Vis Sci 2019;60:4904–4914. doi: 10.1167/iovs.19-27704.

8. Zeinali T, Mansoor B, Mohammadi A, Baradaran B. Regulatory mechanisms of miR-145 expression and the importance of its potential role in cancer. Am J Transl Res 2019;11:6739–6753.

9. Yang J, Xu X, Lin Y, Liu Z, Deng F, Zhou WJ, Yan YN, Wei EB. MicroRNA-145 targets vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009;8:2496–2508. doi: 10.1158/1535-7163.MCT-09-0302.

10. Fan L, Wu Q, Xing X, Wei Y, Shao Z. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai) 2012;44:407–414. doi: 10.1039/abbs/gm019.

11. Filiali M, Missotten GSOA, Maat W, Ly LV, Luyten GPM, Van d WFA, et al. Regulation of VEGF-A in Uveal Melanoma. Investigative Ophthalmology & Visual Science 2010;51:3239. doi: 10.1167/iovs.09-4739.

12. Barak V, Pe’er , Jacob , Kalickman I, Frenkel S. VEGF as a Biomarker for Metastatic Uveal Melanoma in Humans. Current Eye Research 2011;36:386–390. doi: 10.3109/027136809.2010.314573.

13. Filiali ME, Velden PVDA, Luyten GPM, Jager MJ. Anti-angiogenic therapy in uveal melanoma. Dev Ophthalmol 2012;49:117–136. doi: 10.1159/000329591.

14. Nottung G, Missotten GSOA, Sijmons B, Boonman ZFHM, Kreunen JEE, Gabriel VDP. Angiogenic profile of uveal melanoma. Curr Eye Res 2006;31:775–785. doi: 10.1016/j.jfs.2006.05.002.

15. Koch KR, Reitmann AI, Hos D, Schuler SL, Bosch J, Cursiefen C, et al. Autocrine impact of VEGF-A on uveal melanoma cells. Invest Ophthalmol Vis Sci 2014;55:2697–2704. doi: 10.1167/iovs.13-13254.

16. Cheng Y, Liu X, Yang J, Lin Y, Xu DX, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009;105:158–166. doi: 10.1161/circresaha.109.195717.

17. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, et al. MicroRNA-145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010;70:2728–2738. doi: 10.1158/0008-5472.can-09-3718.

18. Lin X, Yang F, Qi X, Li Q, Wang D, Yi T, et al. LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145-Mol. Mol Carcinog. 2015;58:2256–2296. doi: 10.1002/mc.23117.

19. Docrat TF, Nagiah S, Krishnan A, Naidoo DB, Chaturanga AA. Atovorastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact 2018;287:32–40. doi: 10.1016/j.chembiol.2018.04.005.

20. Boufaqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer 2014;21:517–531. doi: 10.1530/ERC-14-0077.

21. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. Biol Chem 2007;282:32582–32590. doi: 10.1074/jbc.m702806200.

22. Liu S, Gao G, Yan D, Chen X, Yao X, Guo S, et al. Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer Med 2017;6:819–833. doi: 10.1002/cam4.1030.

23. Yin Y, Yan ZP, Lu NN, Xu Q, He J, Qian X, et al. Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochem Biophys Acta 2013;1829:239–247. doi: 10.1016/j.bbapap.2012.11.006.

How to cite this article: Yang JY, Li Y, Wang Q, Zhou WJ, Yan NY, Wei WB. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor. Chin Med J 2020;133:1922–1929. doi: 10.1097/CM9.0000000000000875.